drugset / Trial / NCT01143168

Stem Cell Therapy for Type 1 Diabetes Mellitus

NCT01143168

Phase 1 Unknown 24 enrolled Cellonis Biotechnology Co. Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the feasibility, efficacy and safety of transplantation therapy using bone marrow mononuclear cells and umbilical cord mesenchymal stem cells for patients with type 1 diabetes mellitus

Timeline

Start
2010-08
Primary completion
2011-08
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous bone marrow mononuclear cells Cell therapy Other
Subject mesenchymal stem cells Cell therapy Other